Receptor-mediated antiproliferative effects of corticosteroids in Lewis lung tumors

Paul G Braunschweiger, Han L. Ting, Lewis M. Schiffer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Dextran-coated charcoal competitive binding assays and Scatchard analysis revealed the presence of high-affinity, low capacity binding sites for dexamethasone in cytosol preparations from Lewis lung tumors. In vitro studies with live cells indicated approximately 9000 nuclear binding sites/cell for the ligand-receptor complex. In vivo inhibition of cell proliferation by dexamethasone, methylprednisolone and triamcinolone acetonide was found to be dose-dependent. Changes in the [3H]-TdR labeling index, mitotic index and saturable cytosol receptor sites after dexamethasone treatment in vivo suggested a dose-dependent G1 progression delay which, after cessation of dexamethasone treatments, was apparently reversible. Resumption of cell-cycle progression was characterized by synchronous progression through S-phase and correlated temporally with receptor site desaturation. In vivo studies indicated that the effectiveness of vincristine given after dexamethasone was highly sequence-dependent, with the most effective sequence interval being coincident with the interval of maximal S-phase cellularity. Other studies indicated sequential chemotherapy with dexamethasone, vincristine and 5-Fu could be effectively employed, following primary tumor excision, to increase animal survival.

Original languageEnglish
Pages (from-to)427-433
Number of pages7
JournalEuropean Journal of Cancer and Clinical Oncology
Volume20
Issue number3
DOIs
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Dexamethasone
Adrenal Cortex Hormones
Lung
Vincristine
Neoplasms
S Phase
Cytosol
Triamcinolone Acetonide
Withholding Treatment
Mitotic Index
Competitive Binding
Charcoal
Methylprednisolone
Dextrans
Cell Cycle
Binding Sites
Cell Proliferation
Ligands
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Receptor-mediated antiproliferative effects of corticosteroids in Lewis lung tumors. / Braunschweiger, Paul G; Ting, Han L.; Schiffer, Lewis M.

In: European Journal of Cancer and Clinical Oncology, Vol. 20, No. 3, 01.01.1984, p. 427-433.

Research output: Contribution to journalArticle

Braunschweiger, Paul G ; Ting, Han L. ; Schiffer, Lewis M. / Receptor-mediated antiproliferative effects of corticosteroids in Lewis lung tumors. In: European Journal of Cancer and Clinical Oncology. 1984 ; Vol. 20, No. 3. pp. 427-433.
@article{d4fdcf27762e409a962ad640d84b851d,
title = "Receptor-mediated antiproliferative effects of corticosteroids in Lewis lung tumors",
abstract = "Dextran-coated charcoal competitive binding assays and Scatchard analysis revealed the presence of high-affinity, low capacity binding sites for dexamethasone in cytosol preparations from Lewis lung tumors. In vitro studies with live cells indicated approximately 9000 nuclear binding sites/cell for the ligand-receptor complex. In vivo inhibition of cell proliferation by dexamethasone, methylprednisolone and triamcinolone acetonide was found to be dose-dependent. Changes in the [3H]-TdR labeling index, mitotic index and saturable cytosol receptor sites after dexamethasone treatment in vivo suggested a dose-dependent G1 progression delay which, after cessation of dexamethasone treatments, was apparently reversible. Resumption of cell-cycle progression was characterized by synchronous progression through S-phase and correlated temporally with receptor site desaturation. In vivo studies indicated that the effectiveness of vincristine given after dexamethasone was highly sequence-dependent, with the most effective sequence interval being coincident with the interval of maximal S-phase cellularity. Other studies indicated sequential chemotherapy with dexamethasone, vincristine and 5-Fu could be effectively employed, following primary tumor excision, to increase animal survival.",
author = "Braunschweiger, {Paul G} and Ting, {Han L.} and Schiffer, {Lewis M.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1016/0277-5379(84)90092-0",
language = "English",
volume = "20",
pages = "427--433",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "3",

}

TY - JOUR

T1 - Receptor-mediated antiproliferative effects of corticosteroids in Lewis lung tumors

AU - Braunschweiger, Paul G

AU - Ting, Han L.

AU - Schiffer, Lewis M.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Dextran-coated charcoal competitive binding assays and Scatchard analysis revealed the presence of high-affinity, low capacity binding sites for dexamethasone in cytosol preparations from Lewis lung tumors. In vitro studies with live cells indicated approximately 9000 nuclear binding sites/cell for the ligand-receptor complex. In vivo inhibition of cell proliferation by dexamethasone, methylprednisolone and triamcinolone acetonide was found to be dose-dependent. Changes in the [3H]-TdR labeling index, mitotic index and saturable cytosol receptor sites after dexamethasone treatment in vivo suggested a dose-dependent G1 progression delay which, after cessation of dexamethasone treatments, was apparently reversible. Resumption of cell-cycle progression was characterized by synchronous progression through S-phase and correlated temporally with receptor site desaturation. In vivo studies indicated that the effectiveness of vincristine given after dexamethasone was highly sequence-dependent, with the most effective sequence interval being coincident with the interval of maximal S-phase cellularity. Other studies indicated sequential chemotherapy with dexamethasone, vincristine and 5-Fu could be effectively employed, following primary tumor excision, to increase animal survival.

AB - Dextran-coated charcoal competitive binding assays and Scatchard analysis revealed the presence of high-affinity, low capacity binding sites for dexamethasone in cytosol preparations from Lewis lung tumors. In vitro studies with live cells indicated approximately 9000 nuclear binding sites/cell for the ligand-receptor complex. In vivo inhibition of cell proliferation by dexamethasone, methylprednisolone and triamcinolone acetonide was found to be dose-dependent. Changes in the [3H]-TdR labeling index, mitotic index and saturable cytosol receptor sites after dexamethasone treatment in vivo suggested a dose-dependent G1 progression delay which, after cessation of dexamethasone treatments, was apparently reversible. Resumption of cell-cycle progression was characterized by synchronous progression through S-phase and correlated temporally with receptor site desaturation. In vivo studies indicated that the effectiveness of vincristine given after dexamethasone was highly sequence-dependent, with the most effective sequence interval being coincident with the interval of maximal S-phase cellularity. Other studies indicated sequential chemotherapy with dexamethasone, vincristine and 5-Fu could be effectively employed, following primary tumor excision, to increase animal survival.

UR - http://www.scopus.com/inward/record.url?scp=0021326887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021326887&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(84)90092-0

DO - 10.1016/0277-5379(84)90092-0

M3 - Article

VL - 20

SP - 427

EP - 433

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 3

ER -